Newark, New Jersey May 19, 2020 (Issuewire.com) - Alfa Wassermann Diagnostic Technologies, LLC (AWDT) announced today the introduction of a COVID-19 Reagent Panel for follow-up care of vulnerable COVID-19 patients with underlying health conditions. The attached resource, Follow-Up Monitoring of COVID-19 Patients in the Physician Office Laboratory, highlights the importance of monitoring patients with liver, kidney, or cardiovascular conditions as well as those who showed abnormal levels in organ testing after contracting COVID-19. Vulnerable patients in recovery from the virus require continuous monitoring to reduce the risk of increased injury and hospitalization. By monitoring COVID-19 patients, physician office labs will receive the opportunity to help prescribe optimal care and/or applicable therapeutic options under investigation.
Alfa Wassermann Diagnostic Technologies, LLC offers a variety of assays for follow-up monitoring of liver, kidney, and cardiovascular functions for use on the ACE Alera® and ACE Axcel® Clinical Chemistry Systems. For ordering information, please contact a Business Development Manager at Alfa Wassermann Diagnostic Technologies, LLC.
About Alfa Wassermann Diagnostic Technologies, LLC
Alfa Wassermann Diagnostic Technologies, LLC is a leading provider of medical diagnostic instrumentation and reagents to the physician office, veterinary lab, and biopharmaceutical markets. Alfa Wassermann’s diagnostic technology products include the ACE Alera®, ACE Axcel®, and Vet Axcel® clinical chemistry analyzers that are sold around the world to physicians, veterinarians, research laboratories, and other such medical facilities, including many of the leading pharmaceutical companies, academic institutions, and animal conservatories.
Media Contact
Tanya De Boer TDeBoer@AlfaWassermannUS.com 800-220-4488 x265 4 Henderson Drive http://alfawassermannus.com/dt-homepage.asp
